Current and Upcoming Radionuclide Therapies in the Direction of Precision Oncology: A Narrative Review

Overview

Journal Eur J Radiol Open

Specialty Radiology

Date 2023 Feb 14

PMID 36785643

Authors

Hina J Shah

Evan Ruppell

Rozan Bokhari

Parag Aland

Vikram R Lele

Connie Ge

Lacey J McIntosh

Affiliations

Soon will be listed here.

Abstract

As new molecular tracers are identified to target specific receptors, tissue, and tumor types, opportunities arise for the development of both diagnostic tracers and their therapeutic counterparts, termed "theranostics." While diagnostic tracers utilize positron emitters or gamma-emitting radionuclides, their theranostic counterparts are typically bound to beta and alpha emitters, which can deliver specific and localized radiation to targets with minimal collateral damage to uninvolved surrounding structures. This is an exciting time in molecular imaging and therapy and a step towards personalized and precise medicine in which patients who were either without treatment options or not candidates for other therapies now have expanded options, with tangible data showing improved outcomes. This manuscript explores the current state of theranostics, providing background, treatment specifics, and toxicities, and discusses future potential trends.

Citing Articles

Future Prospect of Low-Molecular-Weight Prostate-Specific Membrane Antigen Radioisotopes Labeled as Theranostic Agents for Metastatic Castration-Resistant Prostate Cancer.

Ismuha R, Ritawidya R, Daruwati I, Muchtaridi M Molecules. 2025; 29(24.

PMID: 39770150 PMC: 11679579. DOI: 10.3390/molecules29246062.

Preliminary Study on Lutetium-177 and Gold Nanoparticles: Apoptosis and Radiation Enhancement in Hepatic Cancer Cell Line.

Kouri M, Georgopoulos A, Manios G, Maratou E, Spathis A, Chatziioannou S Curr Issues Mol Biol. 2024; 46(11):12244-12259.

PMID: 39590321 PMC: 11592690. DOI: 10.3390/cimb46110727.

Editorial: Women in radionuclide therapy: 2023.

Lopci E, Matteucci F Front Nucl Med. 2024; 4:1411878.

PMID: 39355213 PMC: 11440981. DOI: 10.3389/fnume.2024.1411878.

The application of radionuclide therapy for breast cancer.

Musket A, Davern S, Elam B, Musich P, Moorman J, Jiang Y Front Nucl Med. 2024; 3:1323514.

PMID: 39355029 PMC: 11440853. DOI: 10.3389/fnume.2023.1323514.

Force Fields, Quantum-Mechanical- and Molecular-Dynamics-Based Descriptors of Radiometal-Chelator Complexes.

Ozturk I, Gervasoni S, Guccione C, Bosin A, Vargiu A, Ruggerone P Molecules. 2024; 29(18).

PMID: 39339411 PMC: 11434398. DOI: 10.3390/molecules29184416.

References

Nagtegaal I, Odze R, Klimstra D, Paradis V, Rugge M, Schirmacher P . The 2019 WHO classification of tumours of the digestive system. Histopathology. 2019; 76(2):182-188. PMC: 7003895. DOI: 10.1111/his.13975. View

Kennedy A . Radioembolization of hepatic tumors. J Gastrointest Oncol. 2014; 5(3):178-89. PMC: 4074949. DOI: 10.3978/j.issn.2078-6891.2014.037. View

Bakker R, Lam M, van Nimwegen S, Rosenberg A, van Es R, Nijsen J . Intratumoral treatment with radioactive beta-emitting microparticles: a systematic review. J Radiat Oncol. 2017; 6(4):323-341. PMC: 5700992. DOI: 10.1007/s13566-017-0315-6. View

Haugen B, Alexander E, Bible K, Doherty G, Mandel S, Nikiforov Y . 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015; 26(1):1-133. PMC: 4739132. DOI: 10.1089/thy.2015.0020. View

Tuttle R, Ahuja S, Avram A, Bernet V, Bourguet P, Daniels G . Controversies, Consensus, and Collaboration in the Use of I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and.... Thyroid. 2019; 29(4):461-470. DOI: 10.1089/thy.2018.0597. View

Wang E, Broadwell S, Bellavia R, Stein J . Selective internal radiation therapy with SIR-Spheres in hepatocellular carcinoma and cholangiocarcinoma. J Gastrointest Oncol. 2017; 8(2):266-278. PMC: 5401864. DOI: 10.21037/jgo.2016.11.08. View

Hope T, Abbott A, Colucci K, Bushnell D, Gardner L, Graham W . NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with Lu-DOTATATE. J Nucl Med. 2019; 60(7):937-943. DOI: 10.2967/jnumed.118.230607. View

Fishbein L, Del Rivero J, Else T, Howe J, Asa S, Cohen D . The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. Pancreas. 2021; 50(4):469-493. DOI: 10.1097/MPA.0000000000001792. View

Srinivas S, Nasr E, Kunam V, Bullen J, Purysko A . Administered activity and outcomes of glass versus resin (90)Y microsphere radioembolization in patients with colorectal liver metastases. J Gastrointest Oncol. 2016; 7(4):530-9. PMC: 4963377. DOI: 10.21037/jgo.2016.03.09. View

10.

Rylova S, Del Pozzo L, Klingeberg C, Tonnesmann R, Illert A, Meyer P . Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody. J Nucl Med. 2015; 57(1):96-102. DOI: 10.2967/jnumed.115.162735. View

11.

Rawla P . Epidemiology of Prostate Cancer. World J Oncol. 2019; 10(2):63-89. PMC: 6497009. DOI: 10.14740/wjon1191. View

12.

Yordanova A, Becker A, Eppard E, Kurpig S, Fisang C, Feldmann G . The impact of repeated cycles of radioligand therapy using [Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2017; 44(9):1473-1479. DOI: 10.1007/s00259-017-3681-9. View

13.

French S, Dubois S, Horn B, Granger M, Hawkins R, Pass A . 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma. Pediatr Blood Cancer. 2012; 60(5):879-84. DOI: 10.1002/pbc.24351. View

14.

Postema E, Boerman O, Oyen W, Raemaekers J, Corstens F . Radioimmunotherapy of B-cell non-Hodgkin's lymphoma. Eur J Nucl Med. 2001; 28(11):1725-35. DOI: 10.1007/s002590100570. View

15.

Entezari P, Gabr A, Kennedy K, Salem R, Lewandowski R . Radiation Lobectomy: An Overview of Concept and Applications, Technical Considerations, Outcomes. Semin Intervent Radiol. 2021; 38(4):419-424. PMC: 8497080. DOI: 10.1055/s-0041-1735530. View

16.

Giammarile F, Chiti A, Lassmann M, Brans B, Flux G . EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging. 2008; 35(5):1039-47. DOI: 10.1007/s00259-008-0715-3. View

17.

Ramage J, Naraev B, Halfdanarson T . Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors. Semin Oncol. 2018; 45(4):236-248. DOI: 10.1053/j.seminoncol.2018.08.004. View

18.

Decarolis B, Schneider C, Hero B, Simon T, Volland R, Roels F . Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study. J Clin Oncol. 2013; 31(7):944-51. DOI: 10.1200/JCO.2012.45.8794. View

19.

Huibregtse K, Vo K, Dubois S, Fetzko S, Neuhaus J, Batra V . Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine. Eur J Cancer. 2016; 66:144-52. PMC: 7523915. DOI: 10.1016/j.ejca.2016.07.017. View

20.

Laidlaw G, Johnson G . Recognizing and Managing Adverse Events in Y-90 Radioembolization. Semin Intervent Radiol. 2021; 38(4):453-459. PMC: 8497076. DOI: 10.1055/s-0041-1735617. View